Edvenswa Enterprises Limited is launching a Rights Issue worth Rs 27.00 crore, available for subscription from 25 October 2024 to 11 November 2024. Shareholders will be entitled to 20 Rights equity shares for every 41 fully paid-up equity shares they own as of the record date, 14 October 2024. Each share has a face value of Rs. 10, and the issue price is set at Rs. 60 per share.
Stay tuned with us for comprehensive details on the Edvenswa Enterprises Ltd 2024 Rights Issue, including the issue size, entitlement, payment terms, and more.
Corporate Action | Details |
---|---|
Security Name | Edvenswa Enterprises Limited |
Issue Open/Close | October 25, 2024 - November 11, 2024 |
Record Date | October 14, 2024 |
Issue Size (Amount) | ₹27.00 Crores |
Issue Size (Shares) | 4,500,000 |
Right Issue Price | ₹60 per share |
Face Value | ₹10 per share |
CMP | ₹66 |
Renunciation of Rights Entitlements | November 5, 2024 |
Terms of Payment | The full amount is payable on application |
Entitlement | 20 Rights Equity Shares for every 41 fully paid-up Equity Shares held on Record Date |
Disclaimer: The Information compiled by CEBPL on a best efforts basis from information CEBPL received from third party vendors, believed to be reliable. The information may contain errors or omissions; and is subject to change without prior or additional notice. CEBPL provides corporate action information that may be of interest or relevance to CEBPL clients. This does not constitute a recommendation or advice by CEBPL, and CEBPL Clients may not rely upon it. CEBPL does not warrant that the information provided is accurate, timely, or complete. CEBPL Clients are urged to verify the information prior to using it in their investing and trading decisions, including, but not limited to, referral to independent financial news resources, company announcements, and regulatory filings or disclosures. "Investment in securities market are subject to market risks, read all the related documents carefully before investing". Registration granted by SEBI and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of retums to investors. Name of Compliance Officer-Prashant Salian Email Id-Prashant.salian@choiceindia.com Contact no. 022-67079999-Ext-2310. Name of Grievance Officer-Deepika Singhvi-Email Id-ig@choiceindia.com, Contact no. 022-67079999-Ext-834. choiceindia.com
Invest in best pharma mutual funds in India for 2020 with Investica. Explore our top recommended pharma mutual funds to start investing today.